Different peptides, different signals
Different peptides do different things because each one signals the body in its own way. Some prompt the release of growth hormone, such as sermorelin and tesamorelin.
Compounding allows pharmacists to create customized medication for an individual patient pursuant to a prescription.
From personalized hormone and ketamine treatments to solving shortages and ensuring quality, compounding fills critical care gaps.
Peptides are short chains of amino acids, the same building blocks that make up proteins. Your body produces thousands of them, and they act as messengers that help regulate everyday functions such as metabolism, growth, sexual function, immune response, and tissue repair.
Some peptides are among the most established medicines in the world. Insulin is a peptide, and GLP-1 medications such as semaglutide and tirzepatide are peptide-based medicines that are FDA-approved and widely prescribed for diabetes and weight management. Other peptides are much less studied, which is part of why the legal and clinical rules around them are still taking shape.
In a clinical setting, peptide therapy means a licensed provider prescribes a specific peptide for a specific patient, and a licensed pharmacy prepares it when doing so is permitted by law. Pharmacy compounding is the practice of preparing a customized medication for an individual patient pursuant to a prescription, often from pure ingredients. Compounded peptide therapy applies that practice to peptides, within the limits of federal and state law.
Different peptides do different things because each one signals the body in its own way. Some prompt the release of growth hormone, such as sermorelin and tesamorelin.
Others are used or studied for sexual health, such as PT-141/bremelanotide. Others, such as GHK-Cu, are used topically in skin applications.
Research into peptides is active and evolving. Not every peptide promoted online has been adequately studied, and not every peptide discussed on social media or sold for "research use" is authorized for use in a compounded prescription. Whether a particular peptide is appropriate for you is a decision for you and your prescriber, based on your health history, other medications, and treatment goals.
A licensed pharmacy cannot simply compound any peptide a patient requests. For a 503A pharmacy to compound a medication from a bulk drug substance, the substance generally must meet at least one of three federal criteria: it must comply with an applicable USP or National Formulary monograph if one exists; if no such monograph exists, it must be a component of an FDA-approved drug; or it must appear on FDA's 503A Bulk Drug Substances List. Other requirements apply as well, including prescription, quality, sourcing, and state-law requirements.
That is why a legitimate pharmacy may decline to prepare many peptides marketed online. The fact that a substance is discussed in research, promoted by a wellness business, or sold on the internet does not mean it may be compounded for human use.
If you have questions about whether a specific peptide can be prepared for you, a licensed compounding pharmacist can walk you through what is and is not permitted. A few peptides may be available through a licensed compounding pharmacy today:
Tesamorelin is associated with an FDA-approved drug product marketed as Egrifta. Whether a compounded preparation is appropriate or lawful depends on the prescription, formulation, source ingredients, and applicable federal and state requirements.
Sermorelin is commonly prepared by compounding pharmacies pursuant to prescription and has been recognized by FDA as eligible for evaluation/use in 503A compounding under FDA's interim bulks framework.
PT-141/bremelanotide is associated with an FDA-approved drug product marketed as Vyleesi and may be compounded only when the applicable legal requirements are met.
GHK-Cu appears on FDA's current interim 503A bulks list for non-injectable routes of administration. Injectable GHK-Cu is a different question and should not be assumed lawful.
Peptide compounding rules are in the middle of a formal FDA review, and the picture is still evolving.
Because this is moving quickly, this page notes the date its status was last reviewed. Confirm the current status with a licensed compounding pharmacy before making any decisions.
In April 2026, FDA removed several peptide bulk drug substances from Category 2, the category FDA uses for nominated substances it has identified as presenting significant safety risks. Removal from Category 2 is not the same thing as authorization to compound. It simply means the substance is no longer in that restricted category and may be evaluated through FDA's 503A bulks-list process.
On July 23 – 24, 2026, FDA's Pharmacy Compounding Advisory Committee reviewed seven peptide-related bulk drug substances for possible inclusion on the 503A Bulk Drug Substances List. The committee recommended six for inclusion: BPC-157-related substances, KPV-related substances, TB-500-related substances, MOTS-c-related substances, Semax-related substances, and Epitalon-related substances. The committee did not recommend emideltide, also known as delta sleep-inducing peptide or DSIP.
A committee recommendation is advisory. FDA still must decide whether and how to proceed, including through formal rulemaking, before those substances could be added to the 503A Bulk Drug Substances List. Until FDA acts, those six peptides are not yet authorized for 503A compounding, and a licensed pharmacy generally may not compound them from bulk drug substance for human use.
That distinction matters: some peptides may be lawful to compound today, but the current FDA discussion is mostly about a different group of peptides that is not lawful yet. Additional substances are expected to be reviewed before February 2027.
There is a clear line between a compounded peptide and the peptides sold across a large online gray market. Products labeled "research use only" or "not for human consumption" are not prepared, checked, prescribed, or dispensed the way a prescription medication is.
A compounded peptide is prepared by a licensed pharmacy, for a named patient, under a prescription, and subject to quality standards and regulatory oversight. That difference is the reason to work with a licensed prescriber and pharmacy rather than sourcing peptides on your own.
Like any medication, peptides can have side effects, and what is right for one person may not be right for another. Your prescriber and pharmacist can help you weigh your health history, other medications, potential risks, and goals. Bring your questions to that conversation, and follow the guidance your prescriber gives you rather than dosing information found online.
The cost of compounded peptide therapy varies by substance, formulation, dose, and pharmacy. Compounded medications are often not covered by insurance, though your situation may differ. A compounding pharmacy can give you a clear price and explain your options before you begin.
Peptide therapy starts with a licensed provider who can determine whether it is appropriate for you. If you are interested, talk with your prescriber, or request a consultation to learn more. To find a compounding pharmacy near you, use our pharmacy locator.
Use this glossary to explore common terms related to peptide therapy, compounding, regulation, and medication safety.
No matching terms found.
Peptide therapy is the use of a prescribed peptide, a short chain of amino acids, under the direction of a licensed provider. When compounded, it is prepared by a licensed pharmacy for an individual patient pursuant to a prescription and within the limits of the law.
A licensed pharmacy can compound a peptide only when the substance and preparation meet federal and state requirements. Peptides that may be available through a compounding pharmacy today include tesamorelin, sermorelin, PT-141/bremelanotide, and non-injectable GHK-Cu, depending on the prescription, formulation, sourcing, and applicable law. Many peptides sold online cannot be lawfully compounded today.
Yes. FDA removed several peptides from Category 2 in April 2026, and in July 2026 an FDA advisory committee recommended six peptide-related substances for possible inclusion on the 503A Bulk Drug Substances List. Those recommendations are not final. FDA must still act before any of them may be compounded from bulk drug substance.
Compounded medications are often not covered by insurance, though coverage varies. A compounding pharmacy can explain the cost and your options before you start.